This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

NPS Pharma: Gattex FDA Panel Preview

Stocks in this article: NPSP

A two-year rat carcinogenicity study of Gattex was performed with clean results. A similar study in mice is still being conducted but NPS Pharma has an agreement with FDA to finish the study after Gattex is approved.

European regulators reviewed all these safety data and found no link between Gattex and cancer.

SBS patients rely on intravenous feeding -- known as parenteral nutrition -- for the liquid nutrients they need to survive. The average SBS patient enrolled in the NPS Pharma studies required approximately 12 liters of parenteral nutrition per week. Gattex works by increasing the nutrient absorption rate of the intestines, thereby reducing the amount of parenteral nutrition that SBS patients require.

In the phase III study, 63% of SBS patients responded to treatment with Gattex after six months compared to 30% of similar patients treated with a placebo. This outcome -- the study's primary endpoint -- was highly statistically significant. Response was defined as a 20% or greater reduction in weekly parenteral nutrition volume.

The phase III study was not conducted under a Special Protocol Agreement with FDA although NPS Pharma has said FDA officials were consulted on the trial design and agreed with the primary endpoint used.

In other analyses of the trial data, Gattex-treated patients reduced their average weekly parenteral nutrition requirements by 4.4 liters, or a 35% reduction. By comparison, placebo patients reduced their parenteral nutrition by 2.3 liters, or 17%. The difference between the two groups was also statistically significant.

Also, 54% of Gattex patients were able to reduce the number of infusion days per week by one or more days, more than double the 23% reduction for placebo-treated patients. Mean body weight of Gattex-treated patients remained unchanged.

Whether or not reductions in parenteral nutrition represent a meaningful clinical benefit for SBS patients is likely to come up as a topic of discussion and debate at next week's FDA advisory panel. European regulators debated the same question and concluded that Gattex provided a meaningful clinical benefit for SBS patients.

Weaning off parenteral nutrition entirely is the best outcome for SBS patients. To date, 8% of Gattex-treated patients have achieved this goal. None of the placebo patients have done so. These patients were treated with Gattex for one year or more.

The FDA drug approval decision date for Gattex is Dec. 28.

--Written by Adam Feuerstein in Boston.

>To contact the writer of this article, click here: Adam Feuerstein.

>To follow the writer on Twitter, go to

>To submit a news tip, send an email to:

Follow TheStreet on Twitter and become a fan on Facebook.

Adam Feuerstein writes regularly for TheStreet. In keeping with company editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback; click here to send him an email.
2 of 2

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 17,804.80 +26.65 0.15%
S&P 500 2,070.65 +9.42 0.46%
NASDAQ 4,765.38 +16.9840 0.36%

Brokerage Partners

Rates from

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs